Replies to post #823378 on NorthWest Biotherapeutics Inc (NWBO)

[skitahoe]

I don't fear conditional approvals, I just hope that we're not forced into a trial that's identical, or nearly identical, to the Phase 3. We're going to do new trials that should not only say how much more we can do, when our vaccine is combined with other therapeutics, but also how many other solid cancers it can benefit. As long as conditional allows these trials to meet the conditions, I'm fine with them.

I believe an Oncologist worth his salt will add Keytruda, Poly-ICLC, or other similar products to his patient treatment, even if it takes a fight to get it, as the result is so improved in early stage trials. If a new trial fails to include these therapeutics in GBM, why would a patient volunteer for a trial offering 13% survival at 5 years when 50% is possible.

Bashers will find something to criticize as long as the people paying them continue to pay. I suspect some of that money may disappear after approval as some move to the long side as bankrupting the company is no longer possible. No matter what the company does, bashers can always find something to call into question. If someone is paying, they'll be around.

Gary

[beartrap12]

I know GZ wrote this in his email to 10Baggerz:

Whether it’s a full or conditional approval remains to be determined, but either way it will enable us to launch DCVax-L in the U.K.

...But I believe he's hedging his bet, covering his a.., or trying to appear like NWBO management is not overly confident or advertising approval before we have approval.

I also think George is not thinking like an investor, but like a scientist, which he should. He's not thinking about what "conditional approval" sounds like to would-be investors.

I don't think DCVax-L needs a conditional approval for n and rGBM because they've already, technically, been through the requirements of conditional approval which, as I understand it, is having the treatment tested in real life on real patients for a certain amount of time. Think compassionate care, which the company has been offering for 4 years. And think of the NHS case-by-case program where the UK already pays for its citizens to get DCVax-L.

No, I think conditional approval for r/n GBM is very unlikely.